Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01)
A Phase II, Randomized Trial of Open-Label Truvada With Darunavir/Ritonavir Versus Multiclass Therapy With Truvada, Darunavir/Ritonavir, Maraviroc and Raltegravir in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects
Sponsor: Aaron Diamond AIDS Research Center
A NA clinical study on HIV Infections, this trial is completed. The trial is conducted by Aaron Diamond AIDS Research Center and has accumulated 9 data snapshots since 2007. Infectious disease trials contribute critical data for public health response and treatment development.
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2023 — Jul 2024 [monthly]
Completed NA
-
Dec 2022 — Jan 2023 [monthly]
Completed NA
-
Jun 2022 — Dec 2022 [monthly]
Completed NA
▶ Show 4 earlier versions
-
Jan 2021 — Jun 2022 [monthly]
Completed NA
-
Jun 2018 — Jan 2021 [monthly]
Completed NA
-
Feb 2017 — Jun 2018 [monthly]
Completed NA
-
Jan 2017 — Feb 2017 [monthly]
Completed NA
First recorded
Oct 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Aaron Diamond AIDS Research Center
- Merck Sharp & Dohme LLC
- Pfizer
- Rockefeller University
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • New York, United States